# A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

> **NCT04964089** · PHASE3 · COMPLETED · sponsor: **Kodiak Sciences Inc** · enrollment: 557 (actual)

## Conditions studied

- Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** KSI-301
- **DRUG:** Aflibercept
- **OTHER:** Sham Procedure

## Key facts

- **NCT ID:** NCT04964089
- **Lead sponsor:** Kodiak Sciences Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-23
- **Primary completion:** 2023-03-28
- **Final completion:** 2023-04-06
- **Target enrollment:** 557 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04964089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04964089, "A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04964089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*